BRPI0407727A - adjuvante de vacina de linfócito humano - Google Patents

adjuvante de vacina de linfócito humano

Info

Publication number
BRPI0407727A
BRPI0407727A BRPI0407727-0A BRPI0407727A BRPI0407727A BR PI0407727 A BRPI0407727 A BR PI0407727A BR PI0407727 A BRPI0407727 A BR PI0407727A BR PI0407727 A BRPI0407727 A BR PI0407727A
Authority
BR
Brazil
Prior art keywords
adjuvant
human lymphocyte
vaccine adjuvant
derived
human
Prior art date
Application number
BRPI0407727-0A
Other languages
English (en)
Inventor
Kenichiro Hasumi
Dean Leo Mann
Kim Graulich Hankey
Kristina Michelle Holt
Original Assignee
Hasumi Llc Dba Shukokai Intern
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34102590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407727(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hasumi Llc Dba Shukokai Intern, Univ Maryland filed Critical Hasumi Llc Dba Shukokai Intern
Publication of BRPI0407727A publication Critical patent/BRPI0407727A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"ADJUVANTE DE VACINA DE LINFóCITO HUMANO". A presente invenção está relacionada a um adjuvante derivado de linfócitos humanos. O adjuvante pode ser usado em combinação com vacinas tradicionais ou imunoterapia de câncer, para melhorar a resposta do sistema imune do paciente a vacina ou a outro agente imunoterapêutico. O adjuvante é derivado a partir de um sobrenadante coletado de linfócitos ativados cultivados.
BRPI0407727-0A 2003-02-21 2004-02-20 adjuvante de vacina de linfócito humano BRPI0407727A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44952803P 2003-02-21 2003-02-21
PCT/US2004/005152 WO2005009397A2 (en) 2003-02-21 2004-02-20 Human lymphocyte vaccine adjuvant

Publications (1)

Publication Number Publication Date
BRPI0407727A true BRPI0407727A (pt) 2006-05-02

Family

ID=34102590

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407727-0A BRPI0407727A (pt) 2003-02-21 2004-02-20 adjuvante de vacina de linfócito humano

Country Status (13)

Country Link
US (2) US7745157B2 (pt)
EP (1) EP1599170B1 (pt)
JP (1) JP5010280B2 (pt)
KR (1) KR20060023519A (pt)
CN (1) CN1787835A (pt)
AR (1) AR045416A1 (pt)
AU (1) AU2004258799A1 (pt)
BR (1) BRPI0407727A (pt)
CA (1) CA2516783A1 (pt)
CL (1) CL2004000340A1 (pt)
MX (1) MXPA05008936A (pt)
RU (1) RU2341289C2 (pt)
WO (1) WO2005009397A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7818101B2 (en) * 2005-12-30 2010-10-19 Canadian National Railway Company System and method for computing rail car switching solutions in a switchyard using an iterative method
AU2006342608A1 (en) * 2006-04-25 2007-11-01 Intercell Ag HCV vaccinations
EP2091334A4 (en) * 2006-10-31 2010-02-03 Hasumi Internat Res Foundation TUMOR TREATMENT BY INJECTION OF DENDRITIC CELLS AND CORRESPONDING VACCINE
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US20140205609A1 (en) * 2013-01-24 2014-07-24 Fred T. Valentine Methods for inducing systemic immune responses to cancer
CN106916783B (zh) * 2013-05-29 2020-07-17 中国科学院分子细胞科学卓越创新中心 肌肉干细胞体外培养方法及其应用
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
WO2016076428A1 (ja) * 2014-11-14 2016-05-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
US20230043806A1 (en) * 2019-02-28 2023-02-09 University Of Virginia Patent Foundation Induction of highly efficacious anti-tumor and immune modulating activity: cell-free off the shelf therapeutic modality

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59116224A (ja) 1982-10-01 1984-07-05 デイミトリ・アダモポ−ロス 免疫反応を抑制する組成物およびその製法
CA2133409C (en) * 1992-04-01 2011-05-24 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US20020142352A1 (en) * 1999-03-04 2002-10-03 Heska Corporation Novel ectoparasite salvia proteins and apparatus to collect such proteins
US6063610A (en) * 1996-11-12 2000-05-16 Heska Corporation Carboxylesterase nucleic acid molecules, proteins and uses thereof
EP1082432A2 (en) * 1998-05-29 2001-03-14 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
EP1086231A2 (en) * 1998-06-12 2001-03-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6573372B2 (en) * 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
US6376246B1 (en) * 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6416977B1 (en) * 1999-04-09 2002-07-09 Heska Corporation Flea chitinase nucleic acid molecules and uses thereof
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
US7736652B2 (en) * 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
NZ536609A (en) * 2002-04-19 2007-11-30 Endocyte Inc Use of an TH1-biasing adjuvant to enhance the immune response to the immunogen in immunotherapy

Also Published As

Publication number Publication date
CA2516783A1 (en) 2005-02-03
JP2007531703A (ja) 2007-11-08
US8088397B2 (en) 2012-01-03
US20040241183A1 (en) 2004-12-02
CL2004000340A1 (es) 2005-05-20
AR045416A1 (es) 2005-10-26
KR20060023519A (ko) 2006-03-14
EP1599170B1 (en) 2013-01-16
EP1599170A4 (en) 2007-05-09
RU2005129134A (ru) 2006-03-27
WO2005009397A3 (en) 2005-11-17
MXPA05008936A (es) 2006-05-25
EP1599170A2 (en) 2005-11-30
CN1787835A (zh) 2006-06-14
US20100266534A1 (en) 2010-10-21
AU2004258799A1 (en) 2005-02-03
RU2341289C2 (ru) 2008-12-20
WO2005009397A2 (en) 2005-02-03
JP5010280B2 (ja) 2012-08-29
US7745157B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
AR022965A1 (es) Vacuna
NO20015073L (no) Vaksiner
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
ATE390933T1 (de) Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
BRPI0607605A2 (pt) moléculas imunogênicas
BR0208675A (pt) Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos
BRPI0407727A (pt) adjuvante de vacina de linfócito humano
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
DE60115051D1 (de) Immunologische adjuvans verbindungen
MY146106A (en) Antiallergic vaccine composition, method for its preparation and use in the treatment of allergic diseases
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
EP1767639A4 (en) ORAL VACCINATE AGAINST PROTOCOIN INFECTION USING A GENTLY CHANGED PLANT
DE602005007177D1 (de) Komplexe mit adjuvanter wirkung
EP2277918A3 (en) Mhc class I and II peptide antigens derived from tumour antigen 5t4
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
WO2002070004A3 (en) Papillomavirus vaccines

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.